Issue link: http://osercommunicationsgroup.uberflip.com/i/365686
C h a i n D ru g s to re D a i l y Tu e s d a y, Au g u s t 2 6 , 2 0 1 4 6 0 As the industry leader in prescrip- tion packaging for over 100 years, Centor remains the same organization: Same People, Same Products, Same Services. Centor Thinks Pink October is Breast Cancer Awareness Month, and pink products continue to line store shelves and displays in sup- port of the cause. That trend now extends to the pharmacy with the availability of pink closures, aimed at helping raise awareness in the fight against breast cancer. Centor, the world's largest supplier of regulatory correct prescription containers, has offered its customers the exclusive opportunity to order pink closures to support the cause. Centor is proud to partner with cus- tomers on efforts of this nature. It's one of the many ways that the company delivers value by helping to promote cus- Centor ( Cont'd. from p. 1) tomers' brands and business. 1-Clic ® is Consumer Preferred Consumers are continually looking for ways to make their daily lives easier and simpler. This is why, in a recent inde- pendent study, Centor's 1-Clic package was selected two to one as the preferred package for dispensed medications. Research shows that 1-Clic is the easiest to open prescription packages. 1- Clic features a tabbed closure that requires minimal pressure and a slight turn for opening, a feature appreciated by seniors. The 1-Clic package is the only prescription package on the market with a commendation for ease of use awarded by the Arthritis Foundation. For a copy of the study, email prescription@centorrx.com or call 800-321-3391. For further information on any of these items, Centor can be reached by email at prescription@centorrx.com or by phone at 800-321-3391. The Centor team is available in booth 622. key therapeutic categories: CNS, including Alzheimer's treatments; gas- troenterology; women's health; urolo- gy; and cardiovascular treatments. The company also has strong portfolios in infectious diseases; respiratory disor- ders, including Cystic Fibrosis; and dermatology treatments. An annual R&D investment of nearly $1 billion will ensure an ongoing stream of devel- opment of new generic and branded products that meet the healthcare needs of patients around the world. In the U.S. generics market, Actavis holds a leading position with an exten- sive portfolio of solid dosage, oral con- trolled and sustained release, transder- mal, injectable, gel, semi-solid and oral transmucosal products in key therapeutic categories. Actavis product in the United States is currently distributed under the Watson and Actavis labels as the compa- ny continues to work through a labeling rebranding initiative following the 2012 combination of Watson Pharmaceuticals and Actavis Group. To ensure continued value for its customers and for patients, Actavis has Actavis ( Cont'd. from p. 1) one of the strongest U.S. generics pipelines, with more than 200 ANDAs on file, nearly 60 of which are first-to-file applications. Products in the generic pipeline represent the company's focused R&D strategy on the development of generics that are difficult to formulate or manufacture or will complement or broaden existing product lines. Actavis leadership in the United States is supported by customer service and a supply chain that is among the best in the industry. Recognized with several Partner and Supplier of the Year awards from key customers, the company is fre- quently acknowledged for its commit- ment to service, fast and smart delivery of product and consistent ability to deliv- er on its promises to customers. Beyond its commercial commit- ments, the new Actavis is enhancing its commitment to Social and Environmental Responsibility, serving as a National Corporate Sponsor for March of Dimes, a Partner in The Medicine Abuse Project and several other local and national not-for-profit organizations. Learn more about Actavis at booth 1840 or visit www.actavis.com. (NIH) cited that "revenues for these serv- ices exceeded their costs when these services were performed by a pharma- cist." The challenge faced in pharmacy today is finding ways to capitalize on these revenue opportunities without sac- rificing patient satisfaction. MarkeTouch Media's RxTouch serv- ice line enables pharmacies to execute and realize their internal goals for clinical patient care. RxTouch allows pharmacies to quantify and measure the outcomes of a wide array of clinical care programs that can be individually configured for each client's expertise. These services are utilized to deliver over 150 million noti- fications and schedule 2MM appoint- ments annually on behalf of over 14,000 pharmacy locations across North America. RxTouch has proven to increase revenue, efficiency and patient satisfaction. The RxTouch Health and Wellness Scheduler provides an electronic plat- form to manage all aspects of an in-store clinic or Health and Wellness campaign, including immunizations, screenings, consultations, classes and store tours. Patients can schedule appointments online, over the phone or in-store based upon the availability pre-set by the phar- macy. Pharmacies can staff appropriately, matching staff hours with the duties scheduled for the day and forecast inven- tory accurately, thus enhancing efficien- cy and profitability. Many chains use this solution to enable "roaming providers" to schedule availability at multiple loca- tions instead of employing clinical staff in every store. The Scheduler can be con- figured for use at the pharmacy and or call center. RxTouch Pharmacist Connect is a fully hosted solution "high touch" patient communication service that increases efficiency and trackable manner. The MarkeTouch ( Cont'd. from p. 1) service was developed specifically to drive star ratings. MarkeTouch has deployed this service to multiple pharma- cy types and has the clinical expertise to guide its clients to launch efficient cam- paigns and gather reporting data. Integrated with most pharmacy systems, data transfer can be customized to each client's needs to ensure that performance and quality goals are met. Additionally, Pharmacist Connect is configurable for a multitude of clinical scenarios including medication therapy management, spe- cialty pharmacy and clinical care. It is flexible to allow MarkeTouch clients to deploy modules as needed to meet their own internal goals. The MarkeTouch staff works with the client's pharmacy team to ensure that each service fits seamlessly into the daily pharmacy workflow and garners high acceptance from the store staff as well as the corpo- rate supervisory teams. Pharmacist Connect's intuitive user interface allows users to quickly isolate patients that meet criteria for services, and documents inter- actions between the pharmacy and patients. With over a decade of experience in Pharmacy, MarkeTouch Media has a proven track record of designing and implementing industry leading solutions. Its collective knowledge and best prac- tices sets its clients at the forefront of Health and Wellness technology. MarkeTouch Media provides a depend- able platform that is customized to meet client goals and includes robust reporting capabilities. All RxTouch services are hosted so no hardware or software is required. This allows pharmacies to implement state of the art technology solutions without investing in costly infrastructure. For more information, visit MarkeTouch Media at booth 307 or online at www.rxtouch.com. AMNEAL'S STRATEGIC INVESTMENTS DRIVE IMPRESSIVE GROWTH To produce the highest quality generic medications for its customers and accel- erate its incredible growth, Amneal Pharmaceuticals LLC is making major investments in research and develop- ment, infrastructure and human capital. The company will spend more than $400 million on R&D and capital improve- ments over the next two years. Strong R&D and a quality-by- design approach are the first steps toward achieving superior finished product quality. Amneal has invested substantially in approximately 200,000 square feet of R&D space among its three metro N.Y. facilities, plus an addi- tional 250,000 square feet at its three sites in India. The firm's scientific team comprises hundreds of Ph.D. and M.D.- level scientists with deep expertise in regulatory, clinical, intellectual proper- ty and other disciplines. Working closely with R&D, Amneal's business development team keenly understands the market landscape and identifies unique, high-value oppor- tunities for the company's portfolio to enhance organic growth. Effective deployment of these resources allows Amneal to target the most attractive com- mercial products across multiple dosage forms and therapeutic categories, a major product development advantage. Amneal continues to invest in the company's nine manufacturing plants in N.Y., N.J. and India. The Brookhaven, N.Y. location will add almost 400,000 square feet, more than doubling produc- tion capacity. In India, significant expan- sion of R&D, API production and fin- ished goods manufacturing is underway to supply products globally, and to a less- er extent for the U.S. Amneal's compre- hensive growth plan calls for maintaining a market presence in high-volume com- modity drugs while aggressively expanding into high-value, differenti- ated products and innovative delivery platforms. The company sees tremen- dous opportunity in complex, difficult- to-formulate specialty generics, novel technologies and advanced dosage forms. Although complex dosage forms now comprise a smaller market, it will expand rapidly as an estimated $36 billion worth of differentiated generics lose patent protection over the next several years. With increasing margin pressure on commodities, sourcing these advanced medications will be a notable differentiator, enabling Amneal to sustain and accel- erate growth long-term. To expand internationally, Amneal has established front-end marketing and distribution capabilities in the U.K., Spain, Germany, the Nordic countries, Switzerland and Australia. The firm is also pur- suing acquisitions and evaluat- ing strategic partners in Japan, Southeast Asia and Latin America. Finally, Amneal has invested consid- erable resources in human capital as well as product development for each new market it enters. The firm now employs more than 2,600 worldwide. These forward-thinking investments have made Amneal one of the fastest- growing generic manufacturers in the U.S. and a recognized market leader. But no matter how quickly it grows, Amneal remains dedicated to delivering superb quality products, creating superior cus- tomer value and treating employees like family – the company's guiding princi- ples since the beginning and the reasons for its tremendous success. For more information, visit Amneal at booth 916, go to www.amneal.com or call 866-525-7270.